Page 2 - Head External News Today

Pratteln, Switzerland, February 18, 2022 - Santhera Pharmaceuticals (SIX: SANN) announces full redemption of its senior unsecured convertible bonds (the 2017/22 Bonds, ISIN CH0353955195), effective

Pratteln, Switzerland, December 15, 2021 - Santhera Pharmaceuticals (SIX: SANN) announces that its shareholders have approved all proposals by the Board of Directors at the Extraordinary General Meeting

Investegate announcements from Santhera Pharmaceuticals Holdi, Santhera’s Shareholders Approve all Board Proposals at Today’s Extraordinary General Meeting

Pratteln, Switzerland, December 6, 2021 - Santhera Pharmaceuticals (SIX: SANN) is pleased to invite investors, shareholders, media representatives and interested parties to join a conference call

Ad hoc announcement pursuant to Art. 53 LR Vamorolone given throughout the study showed sustained efficacy across multiple endpoints over 48 weeks and the...

Ad hoc announcement pursuant to Art. 53 LR Vamorolone given throughout the study showed sustained efficacy across multiple endpoints over 48 weeks and the good safety and tolerability profile

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, November 4, 2021 - Santhera Pharmaceuticals (SIX: SANN) announces the appointment of Stephanie Brown as President North America and

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, November 4, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces the appointment of...

Santhera Appoints Stephanie Brown as President North America and Member of the Executive Management Team - read this article along with other careers information, tips and advice on BioSpace

Ad hoc announcement pursuant to Art. 53 LR Cash and cash equivalents of CHF 8.0 million (as of June 30, 2021)Net revenue CHF 4.5 million (H1-2020: CHF 7.8 million)Net result for period of CHF -20.5